Dr. Sarah J. McKillop
Claim this profileUniversity of Alberta Hospital
Expert in Cancer
Studies Childhood Cancer
28 reported clinical trials
69 drugs studied
About Sarah J. McKillop
Education:
- Holds an MD (Doctor of Medicine).
- Earned an MSc (Master of Science).
Experience:
- Serves as a clinical researcher and specialist at the University of Alberta Department of Pediatrics, with ties to the Cross Cancer Institute.
- Contributed to research published in the Journal of Adolescent and Young Adult Oncology, examining the effects of the Adolescent and Young Adult Oncology Navigator program on young cancer patients' access to oncology psychosocial services.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Childhood Cancer
BCR-ABL1 fusion positive
ABL-class fusion positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Sarah J. McKillop is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Selinexor + Radiation
for Brain Cancer
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Recruiting1 award Phase 1 & 21 criteria
More about Sarah J. McKillop
Clinical Trial Related5 years of experience running clinical trials · Led 28 trials as a Principal Investigator · 16 Active Clinical TrialsTreatments Sarah J. McKillop has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Laboratory Biomarker Analysis
- Radiation Therapy
- Cytology Specimen Collection Procedure
Breakdown of trials Sarah J. McKillop has run
Cancer
Childhood Cancer
Acute Lymphoblastic Leukemia
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sarah J. McKillop specialize in?
Sarah J. McKillop focuses on Cancer and Childhood Cancer. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Sarah J. McKillop currently recruiting for clinical trials?
Yes, Sarah J. McKillop is currently recruiting for 12 clinical trials in Edmonton Alberta. If you're interested in participating, you should apply.
Are there any treatments that Sarah J. McKillop has studied deeply?
Yes, Sarah J. McKillop has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Sarah J. McKillop?
Apply for one of the trials that Sarah J. McKillop is conducting.
What is the office address of Sarah J. McKillop?
The office of Sarah J. McKillop is located at: University of Alberta Hospital, Edmonton, Alberta T6G 2B7 Canada. This is the address for their practice at the University of Alberta Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.